Previous studies suggested that PLK1 inhibition by Volasertib promotes the degradation of PAX3-FOXO1, a fusion protein frequently found in rhabdomyosarcoma patients, thereby inhibiting cancer growth in PDX models (Abbou et al, 2016). Here, FOXO1 is linked to rhabdomyosarcoma.